Many GLP-1 drugs in the pipeline for management in #OA #ACR25 @rheumnow https://t.co/y3UCp0CcUb

Semaglitide did help in weight loss and decrease in pain in knee OA https://t.co/240sR5An3m #acr25 @rheumnow Question is that is the pain decrease is secondary to weight loss or an independent effect? https://t.co/R2v5YDP3A5

GLP-1 receptor agonists reduce mortality in PsA Tsibadze et al retrospectively compared ~4k PsA on GLP-1 to ~86k PsA not After propensity matching, those treated with GLP-1: - lower risk MACE - lower risk overall death @RheumNow #ACR25 Abst 0849 https://t.co/EuojrDq0Fj

Is MTX worth anything in GCA? METOGiA: MTX 52w vs TCZ 52w for GCA MTX didn’t achieve non-inferiority to TCZ, but: - clearly it does something - continue both >1y: after MTX/TCZ therapy ended, they ended up with same relapse-free survival, cumulative GC #ACR25 ABST0891 @RheumNow https://t.co/WvvkHKIXuQ

In pooled PsA trials (n=1222), deucravacitinib reduced disease activity–linked proteomic scores in both sexes by Week 16. Proteomic profiling identified 133 unique proteins in males and 177 in females vs sex-matched healthy controls. Females showed greater enrichment in https://t.co/TTAWUtOLP0

#ACR25 Abstr#1535 This is super-cool & watch this space! Novel Bi-specific T-cell Engager using pan-gamma delta TCR instead of currently used CD3. In vitro study = complete B-cell depletion comparable to other BiTE, but with a more favorable cytokine release profile @RheumNow https://t.co/PtR5g3gCPH

Sex based differences in PsA proteomics Analyse from POETYK PSA 1 & 2 deucravacitinib RCT Large overlap but female pts specificities, Upregulation of: -JAK STAT pathway -Cytokine interaction Linked with higher disease activity in female groups Yes Correlation, but not https://t.co/VwiVOkxpoB

Open-label MTX vs. Toci in GCA in METOGiA Wk 78: 37% w/o relapse in MTX arm 46% w/o relapse in Toci arm MTX was NOT non-inferior to Toci Toci superior in 2ndary endpoints Cumulative doses GC not significantly different #ACR25 #ACRBest @RheumNow Abst 0891 https://t.co/lCaP4EdJ9C

List of GLP1 agonists approved currently..would they have effects in #OA Session title is should we gave them to everyone? #ACR25 @RheumNow https://t.co/dXwB6Jkg8C

HOPE for Pts w #fibromyalgia #FM #Transcutaneous #electrical #nerve #stimulation + #physio Is Better than #PT alone #Pragmatic #cluster #randomized #trial Answered impt question Does #TENS help Pts w #fibro Too ba noTENS sham Abst#LB03 #ACR25 #ACRBest @RheumNow @ACRheum https://t.co/fGyAugFtcN

Open label noninferiority RCT "METOGiA" in GCA TCZ improved relapse free survival (83% vs 67% MTX) & pred free remission (81% vs 61% MTX) wk 52. Ignore the weird primary endpt at week 78 Everyone also got pred; are we sure MTX works at all? @RheumNow #ACR25 #ACRBest Abstr#0891 https://t.co/i48JBnawB7